BETA
Your AI-Trained Oncology Knowledge Connection!
Stay up to date on recent advances in the multidisciplinary approach to cancer.
FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer
Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months in patients with platinum-resistant ovarian cancer.
Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC
According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.
Developers Resubmit BLA for Tab-Cel in EBV+ Lymphoproliferative Disease
The FDA lifted a clinical hold on a new drug application for tabelecleucel as a treatment for EBV-positive lymphoproliferative disease in May 2025.
Best Practices for the Medical Oncology Boards
A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.
Avutometinib/Defactinib Display Safety, Efficacy in Ovarian Cancer Subtype
Among 115 patients treated with avutometinib and defactinib, only 5 deaths occurred in the study, none of which were related to study treatment.
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
